{"id":34793,"date":"2025-06-05T18:26:25","date_gmt":"2025-06-05T10:26:25","guid":{"rendered":"https:\/\/flcube.com\/?p=34793"},"modified":"2025-06-05T18:26:26","modified_gmt":"2025-06-05T10:26:26","slug":"genrix-bio-partners-with-cullinan-therapeutics-for-gr1803-license","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34793","title":{"rendered":"Genrix Bio Partners with Cullinan Therapeutics for GR1803 License"},"content":{"rendered":"\n<p>China-based Chongqing Genrix Biopharmaceutical Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/688443:SHA\">SHA: 688443<\/a>) announced a licensing agreement with Cullinan Therapeutics, Inc. (CGEM). The deal grants Cullinan exclusive development, manufacturing, and commercialization rights to Genrix Bio&#8217;s GR1803 outside Greater China (including Hong Kong, Macau, and Taiwan). Genrix Bio retains all rights in Greater China and plans to explore the use of GR1803 in autoimmune diseases within mainland China, conducting clinical trials and providing clinical data to Cullinan under a paid licensing arrangement.<\/p>\n\n\n\n<p><strong>Financial Terms<\/strong><br>Under the agreement, Cullinan will pay up to USD 712 million in total, including a USD 20 million upfront payment, up to USD 292 million in development and regulatory milestone payments, and up to USD 400 million in sales-based milestone payments. Additionally, Cullinan will pay tiered royalties on net sales in the licensed territories, reaching up to the mid-double-digit percentage range.<\/p>\n\n\n\n<p><strong>GR1803 Technology and Development<\/strong><br>GR1803 is a bispecific antibody targeting both BCMA and CD3. It redirects cytotoxic T cells to BCMA-expressing cells, with high affinity for BCMA and low affinity for CD3 (100-fold higher selectivity for BCMA). This design ensures effective T-cell recruitment and activation while minimizing off-target effects. GR1803 received clinical trial approval from China\u2019s NMPA for multiple myeloma (MM) in January 2022 and Breakthrough Therapy Designation (BTD) in August 2023. It is currently in a Phase II study for relapsed\/refractory MM in China.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/688443_20250605_I0UJ.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688443_20250605_I0UJ.\"><\/object><a id=\"wp-block-file--media-9d7a6217-ddf4-490e-a6df-916b4a3c34d8\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/688443_20250605_I0UJ.pdf\">688443_20250605_I0UJ<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/688443_20250605_I0UJ.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9d7a6217-ddf4-490e-a6df-916b4a3c34d8\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced a licensing agreement with Cullinan Therapeutics,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":34795,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,2537,3000,28,877,2790],"class_list":["post-34793","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-cullinan-oncology","tag-genrix-biopharmaceutical","tag-multi-specific-antibodies","tag-sha-688443","tag-t-cell-engager"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Genrix Bio Partners with Cullinan Therapeutics for GR1803 License - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced a licensing agreement with Cullinan Therapeutics, Inc. (CGEM). The deal grants Cullinan exclusive development, manufacturing, and commercialization rights to Genrix Bio&#039;s GR1803 outside Greater China (including Hong Kong, Macau, and Taiwan). Genrix Bio retains all rights in Greater China and plans to explore the use of GR1803 in autoimmune diseases within mainland China, conducting clinical trials and providing clinical data to Cullinan under a paid licensing arrangement.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34793\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genrix Bio Partners with Cullinan Therapeutics for GR1803 License\" \/>\n<meta property=\"og:description\" content=\"China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced a licensing agreement with Cullinan Therapeutics, Inc. (CGEM). The deal grants Cullinan exclusive development, manufacturing, and commercialization rights to Genrix Bio&#039;s GR1803 outside Greater China (including Hong Kong, Macau, and Taiwan). Genrix Bio retains all rights in Greater China and plans to explore the use of GR1803 in autoimmune diseases within mainland China, conducting clinical trials and providing clinical data to Cullinan under a paid licensing arrangement.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34793\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-05T10:26:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-05T10:26:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0511.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34793#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34793\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Genrix Bio Partners with Cullinan Therapeutics for GR1803 License\",\"datePublished\":\"2025-06-05T10:26:25+00:00\",\"dateModified\":\"2025-06-05T10:26:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34793\"},\"wordCount\":236,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34793#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0511.webp\",\"keywords\":[\"Cancer\",\"Cullinan Oncology\",\"Genrix Biopharmaceutical\",\"Multi-specific antibodies\",\"SHA: 688443\",\"T cell engager\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34793#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34793\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34793\",\"name\":\"Genrix Bio Partners with Cullinan Therapeutics for GR1803 License - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34793#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34793#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0511.webp\",\"datePublished\":\"2025-06-05T10:26:25+00:00\",\"dateModified\":\"2025-06-05T10:26:26+00:00\",\"description\":\"China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced a licensing agreement with Cullinan Therapeutics, Inc. (CGEM). The deal grants Cullinan exclusive development, manufacturing, and commercialization rights to Genrix Bio's GR1803 outside Greater China (including Hong Kong, Macau, and Taiwan). Genrix Bio retains all rights in Greater China and plans to explore the use of GR1803 in autoimmune diseases within mainland China, conducting clinical trials and providing clinical data to Cullinan under a paid licensing arrangement.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34793#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34793\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34793#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0511.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0511.webp\",\"width\":1080,\"height\":608,\"caption\":\"Genrix Bio Partners with Cullinan Therapeutics for GR1803 License\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34793#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genrix Bio Partners with Cullinan Therapeutics for GR1803 License\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Genrix Bio Partners with Cullinan Therapeutics for GR1803 License - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced a licensing agreement with Cullinan Therapeutics, Inc. (CGEM). The deal grants Cullinan exclusive development, manufacturing, and commercialization rights to Genrix Bio's GR1803 outside Greater China (including Hong Kong, Macau, and Taiwan). Genrix Bio retains all rights in Greater China and plans to explore the use of GR1803 in autoimmune diseases within mainland China, conducting clinical trials and providing clinical data to Cullinan under a paid licensing arrangement.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34793","og_locale":"en_US","og_type":"article","og_title":"Genrix Bio Partners with Cullinan Therapeutics for GR1803 License","og_description":"China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced a licensing agreement with Cullinan Therapeutics, Inc. (CGEM). The deal grants Cullinan exclusive development, manufacturing, and commercialization rights to Genrix Bio's GR1803 outside Greater China (including Hong Kong, Macau, and Taiwan). Genrix Bio retains all rights in Greater China and plans to explore the use of GR1803 in autoimmune diseases within mainland China, conducting clinical trials and providing clinical data to Cullinan under a paid licensing arrangement.","og_url":"https:\/\/flcube.com\/?p=34793","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-05T10:26:25+00:00","article_modified_time":"2025-06-05T10:26:26+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0511.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34793#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34793"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Genrix Bio Partners with Cullinan Therapeutics for GR1803 License","datePublished":"2025-06-05T10:26:25+00:00","dateModified":"2025-06-05T10:26:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34793"},"wordCount":236,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34793#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0511.webp","keywords":["Cancer","Cullinan Oncology","Genrix Biopharmaceutical","Multi-specific antibodies","SHA: 688443","T cell engager"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34793#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34793","url":"https:\/\/flcube.com\/?p=34793","name":"Genrix Bio Partners with Cullinan Therapeutics for GR1803 License - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34793#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34793#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0511.webp","datePublished":"2025-06-05T10:26:25+00:00","dateModified":"2025-06-05T10:26:26+00:00","description":"China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced a licensing agreement with Cullinan Therapeutics, Inc. (CGEM). The deal grants Cullinan exclusive development, manufacturing, and commercialization rights to Genrix Bio's GR1803 outside Greater China (including Hong Kong, Macau, and Taiwan). Genrix Bio retains all rights in Greater China and plans to explore the use of GR1803 in autoimmune diseases within mainland China, conducting clinical trials and providing clinical data to Cullinan under a paid licensing arrangement.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34793#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34793"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34793#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0511.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0511.webp","width":1080,"height":608,"caption":"Genrix Bio Partners with Cullinan Therapeutics for GR1803 License"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34793#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Genrix Bio Partners with Cullinan Therapeutics for GR1803 License"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0511.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34793"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34793\/revisions"}],"predecessor-version":[{"id":34796,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34793\/revisions\/34796"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34795"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34793"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34793"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}